Substance / Medication

Cenegermin

Overview

Active Ingredient
cenegermin
RxNorm CUI
2104332

Indications

® OXERVATE(cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.

Labeler: Dompé farmaceutici S.p.A.Updated: 2025-02-05T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Topical Cenegermin for Pediatric Neurotrophic Keratopathy: A Review of the Literature and Systematic Review.
Bakr Mohammad, Eleiwa Taher K, Saeed Hajirah N et al. · Cornea · 2025
PMID: 40815061Meta-Analysis
Amniotic membrane graft (AMG) for persistent epithelial defects following infective corneal ulcers and keratitis - A systematic review.
Thevi Thanigasalam, Abas Adinegara L, Dua Harminder S · Indian J Ophthalmol · 2025
PMID: 39257085Meta-AnalysisFull text (PMC)
Ophthalmic Manifestations of the Mpox Virus: A Systematic Review and Meta-analysis.
Rohilla Shivam, Gaidhane Shilpa, Balaraman Ashok Kumar et al. · J Infect Dis · 2025
PMID: 39913333Meta-Analysis
An Emerging Global Threat of Mycotic Keratitis Caused by Uncommon Fungal Species: A Systematic Review and Meta-Analysis.
Gautam Megha, Lal Babu, Patel Smita et al. · Transl Vis Sci Technol · 2025
PMID: 40172527Meta-AnalysisFull text (PMC)
Corneal cross-linking for infectious keratitis of various causes: an umbrella review.
Farhadi Fereshteh, Salehi-Pourmehr Hanieh, Arasteh Amin et al. · BMC Ophthalmol · 2025
PMID: 40269767Meta-AnalysisFull text (PMC)
Topical antibiotics for treating bacterial keratitis: a network meta-analysis.
Song Anna, Yang Yunfei, Henein Christin et al. · Cochrane Database Syst Rev · 2025
PMID: 40728038Meta-AnalysisFull text (PMC)
Cochlear implantation in patients with keratitis-ichthyosis-deafness syndrome: A systematic review.
Pearce Alexa N, Farsi Soroush, Saadi Carissa C et al. · Int J Pediatr Otorhinolaryngol · 2025
PMID: 40889428Meta-Analysis
Incidence, causative pathogens, risk factors, geographical variations, and outcomes of post-keratoplasty infectious keratitis over the last 15 years: a systematic review and meta-analysis.
Ridwan Asri Salima, Putera Ikhwanuliman, Ridwan Alifaturrasyid Syafaatullah et al. · Int Ophthalmol · 2025
PMID: 41205081Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cenegermin (substance)
SNOMED CT
773954004
UMLS CUI
C4541383
RxNorm CUI
2104332
Labeler
Dompé farmaceutici S.p.A.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.